欧洲单中心应用原位开窗TEVAR治疗主动脉弓病变的经验
单中心连续26例主动脉弓病变患者接受原位开窗TEVAR,技术成功率为92%(24/26),围术期主要卒中2例(7.6%),单开窗和双开窗组无死亡,三开窗组3例中2例围术期死亡。作者认为该技术尤其适用于急诊,三开窗仅作为急诊补救措施,需更大样本和多中心研究证实。
要点
- 原位开窗TEVAR技术成功率为92%(24/26),2例穿刺失败。
- 围术期主要卒中2例(7.6%),三开窗组3例中2例围术期死亡。
- 随访期间2例(7.6%)需晚期非计划再干预,无动脉瘤或手术相关死亡。
核心结论
- 作者认为专用穿刺针装置有效,原位开窗TEVAR可作为主动脉弓病变的现货型血管内治疗初始方法,尤其在急性情况下。
- 作者认为三开窗应仅作为急诊病例的补救措施。
- 作者指出需要更大样本和多中心研究来证实这些结果。
研究设计与样本
- 单中心研究,纳入2021年7月至2024年2月期间接受原位开窗覆膜支架治疗的连续26例胸部病变患者(24例男性;中位年龄69±10岁)。
- 病变包括16例动脉瘤、6例B型夹层和4例穿透性主动脉溃疡(PAU),均累及主动脉弓且左锁骨下动脉(LSA)远端无足够近端锚定区(PLZ)。
- 27%(7/26)患者为急诊/紧急情况(有症状或包裹性破裂)。
- 21例、2例和3例患者分别行单开窗(LSA)、双开窗(LSA和左颈总动脉LCCA)和三开窗(全弓)。
- 围术期和随访数据(术后、3个月、6个月和每年)前瞻性收集,结果和影像扫描回顾性评估和分析。
主要发现
- 技术成功(定义为血管内隔绝主动脉弓病变并原位开窗保留弓上血管)为92%(24/26例),2例穿刺失败。
- 仅1例主动脉夹层患者(3.8%)出现Ia型内漏,1个月后自行缓解。
- 早期围术期神经系统事件3例(11.5%),其中2例发生主要卒中(7.6%)。
- 单开窗和双开窗组无死亡;三开窗组3例中2例围术期死亡,均为急诊/紧急指征。
- 平均随访18个月(范围2-32),随访期间2例(7.6%)需晚期非计划再干预,1例发生短暂性脑缺血发作,无动脉瘤或手术相关死亡,末次随访无内漏、分支闭塞、桥接支架断裂或移位。
临床怎么用
- 作者认为原位开窗TEVAR可作为主动脉弓病变的现货型血管内治疗初始方法,尤其在急性情况下。
- 作者认为三开窗应仅作为急诊病例的补救措施。
局限性
- 原文指出需要更大样本和多中心研究来证实这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: We demonstrate our experience and outcomes of in situ fenestration (ISF) using a dedicated needle perforation device to preserve the supra-aortic vessels of the aortic arch during thoracic endovascular aortic repair (TEVAR). Methods: We included all patients with thoracic pathologies who were treated using the in situ fenestrated endografts between July 2021 and February 2024. A consecutive series of 26 patients (24 men; median age 69±10 years) received ISF TEVAR. All pathologies (16 aneurysms, 6 type B dissections, and 4 penetrating aortic ulcer [PAU]) involved the aortic arch without sufficient proximal landing zone (PLZ) distal of the left subclavian artery (LSA). Twenty-seven percent of the patients (7/26) presented in an emergent/urgent situation (symptomatic or contained rupture). One (LSA), double (LSA and left common carotid artery LCCA), and 3 (total arch) fenestrations were performed in 21, 2, and 3 patients, respectively. The perioperative and follow-up data (postoperative, 3 and 6 months, and annually) were prospectively collected. Outcomes and imaging scans were evaluated and analyzed retrospectively. Results: The technical success, defined as endovascular exclusion of the aortic arch pathology and preservation of the supra-aortic vessels using ISF, was achieved in 92% (24/26 patients). The needle perforation failed in 2 of the patients. Only one patient with aortic dissection (3.8%) had an endoleak type Ia, which resolved spontaneously after 1 month. The early perioperative neurological events occurred in 3 patients (11.5%). Two of them suffered a major stroke (7.6%). There were no mortalities in the mono and double ISF groups. However, the perioperative mortalities encountered in 2 of 3 patients in the triple ISF group, both of whom were treated due to emergent or urgent indications. The mean follow-up period was 18 months (range: 2-32). During the follow-up, 2 patients required late unplanned re-interventions (7.6%). Further transient ischemic attack occurred in one patient. No patients died due to aneurysm or procedure-related causes. At the last follow-up, no endoleaks, branch occlusion, bridging stent fractures, or dislocation were registered. Conclusion: In our experience, the use of dedicated needle device is efficacious. ISF TEVAR may serve as an initial approach as off-the-shelf endovascular treatment of the aortic arch pathologies, especially in acute situations. The triple ISF should be considered only as bailout procedure in the emergent cases. Larger series and multicenter studies are of course needed to corroborate these results.Clinical ImpactOur study demonstrated the clinical impact in real-world practice of using In-situ fenestration TEVAR with the innovative dedicated perforation-needle technique, which is characterized by an immediate availability as off-the-shelf device, compatibility with the various pathologies and anatomies, as well as minimal invasiveness in comparison to the debranching bypass-procedure for the preservation of the supra-aortic vessels during the endovascular repair of aortic arch pathologies. According to center experience, this approach can applied in elective cases, however, due to its practicability, it can be especially valuable in emergencies, when the other methods are considered as an unfavorable.
引用
- Youssef M, Gunaseelan M, Jawish F, et al. European Single-Center Experience Using In Situ Fenestration TEVAR in Treating the Aortic Arch Pathologies. J Endovasc Ther. 2025. PMID: 39957260. doi:10.1177/15266028251316780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。